{"doi":"10.1210/jendso/bvaf182","title":"Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance","abstract":"Abstract Context Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective therapies for diabetes mellitus and obesity. Their effect on nonmedullary thyroid malignancies remains unclear. Objective To evaluate the impact of GLP-1RA exposure on tumor kinetics of patients with low-risk papillary thyroid carcinoma undergoing active surveillance (AS). Design Retrospective observational cohort study of 18 patients with 19 papillary thyroid carcinomas (≤1.5 cm) exposed to GLP-1RA matched 1:2 by body mass index and tumor size to 37 patients with 38 carcinomas never exposed to GLP-1RA and undergoing AS at a single tertiary center for a median of 5.5 years. Main outcome Tumor growth/shrinkage was considered significant when any diameter changed by ≥3 mm and/or volume changed >72%. Tumor volume doubling time was calculated in a subset of patients off and on GLP-1RA therapy. Results After a median GLP-1RA exposure of 25 months [interquartile range: 14-34] and a median follow-up of 5.5 years, 2/19 (10.5%) tumors exposed to GLP-1RA exhibited significant volume growth, 1 (5.3%) decreased, and 16 (84.2%) remained stable, whereas 1/38 (2.6%) carcinomas not exposed to GLP-1RA showed >72% volume increase, 2/38 (5.3%) decreased, and 35/38 (92.1%) remained stable, P = .53. GLP-1RA exposure did not alter tumor volume growth kinetics in either of the 2 tumors that increased over time. Conclusion GLP-1RA therapy does not affect tumor growth kinetics in patients with low-risk papillary thyroid carcinoma on AS. Further studies with larger cohorts and extended follow-up are warranted to validate the safety of GLP-1RA use in patients with thyroid carcinomas undergoing active surveillance.","journal":"Journal of the Endocrine Society","year":2025,"id":535395,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8852,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":606988,"name":"Samantha Newman","orcid":"0000-0003-2404-4318","position":1,"is_corresponding":false},{"id":55870,"name":"R. Michael Tuttle","orcid":"0000-0001-9899-9702","position":2,"is_corresponding":false},{"id":108811,"name":"Laura Boucai","orcid":"0000-0002-8852-1120","position":3,"is_corresponding":false},{"id":1249607,"name":"Armando Patrizio","orcid":"0000-0003-1090-4794","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-19T02:51:56.297114Z","pmid":"41376649","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}